Esperion Therapeutics Inc (ESPR.OQ) Company Profile | Reuters.com
Edition:
United States

Profile: Esperion Therapeutics Inc (ESPR.OQ)

ESPR.OQ on NASDAQ Stock Exchange Global Market

16.12USD
24 Jun 2016
Change (% chg)

$-0.78 (-4.62%)
Prev Close
$16.90
Open
$15.80
Day's High
$17.14
Day's Low
$15.80
Volume
279,484
Avg. Vol
131,846
52-wk High
$100.79
52-wk Low
$12.61

Esperion Therapeutics, Inc., incorporated on January 22, 2008, is a pharmaceutical company. The Company is focused on developing and commercializing oral, low-density lipoprotein cholesterol (LDL-C) lowering therapies for the treatment of patients with elevated LDL-C. The Company's segment is the business of researching, developing and commercializing therapies for the treatment of patients with elevated LDL-C. The Company's lead product candidate is ETC-1002, or bempedoic acid. The Company is engaged in conducting a global Phase III long-term safety and tolerability study of bempedoic acid in patients with hyperlipidemia whose LDL-C is not adequately controlled with low- and moderate-dose statins.

Bempedoic Acid

Bempedoic acid is an inhibitor of ATP Citrate Lyase (ACL), a well-characterized enzyme on the cholesterol biosynthesis pathway. Bempedoic acid inhibits cholesterol synthesis in the liver, decreases intracellular cholesterol and up-regulates LDL-receptors. Bempedoic acid is converted to the coenzyme A (CoA) form in the liver, a required biochemical step for the inhibition of ACL, an enzyme upstream of Hydroxymethylglutaryl (HMG)-CoA reductase.

Company Address

Esperion Therapeutics Inc

3891 RANCHERO DRIVE, SUITE 150
ANN ARBOR   MI   48108
P: +1734.8873903
F: +1302.6555049

Company Web Links